| JANÍKOVÁ, Andrea, Zbyněk BORTLÍČEK, Vit CAMPR, Natasa KOPALOVA, Katerina BENESOVA, David BELADA, Vit PROCHAZKA, Robert PYTLIK, Samuel VOKURKA, Jan PIRNOS, Juraj DURAS, Heidi MOCIKOVA, Jiří MAYER a Marek TRNENY. Radiotherapy with rituximab may be better than radiotherapy alone in first-line treatment of earlystage follicular lymphoma: is it time to change the standard strategy? Leukemia & Lymphoma. London: Informa Healthcare, 2015, roč. 56, č. 8, s. 2350-2356. ISSN 1042-8194. Dostupné z: https://dx.doi.org/10.3109/10428194.2014.990010. |
Další formáty:
BibTeX
LaTeX
RIS
@article{1318860,
author = {Janíková, Andrea and Bortlíček, Zbyněk and Campr, Vit and Kopalova, Natasa and Benesova, Katerina and Belada, David and Prochazka, Vit and Pytlik, Robert and Vokurka, Samuel and Pirnos, Jan and Duras, Juraj and Mocikova, Heidi and Mayer, Jiří and Trneny, Marek},
article_location = {London},
article_number = {8},
doi = {http://dx.doi.org/10.3109/10428194.2014.990010},
keywords = {Follicular lymphoma; rituximab; radiotherapy},
language = {eng},
issn = {1042-8194},
journal = {Leukemia & Lymphoma},
title = {Radiotherapy with rituximab may be better than radiotherapy alone in first-line treatment of earlystage follicular lymphoma: is it time to change the standard strategy?},
volume = {56},
year = {2015}
}
TY - JOUR
ID - 1318860
AU - Janíková, Andrea - Bortlíček, Zbyněk - Campr, Vit - Kopalova, Natasa - Benesova, Katerina - Belada, David - Prochazka, Vit - Pytlik, Robert - Vokurka, Samuel - Pirnos, Jan - Duras, Juraj - Mocikova, Heidi - Mayer, Jiří - Trneny, Marek
PY - 2015
TI - Radiotherapy with rituximab may be better than radiotherapy alone in first-line treatment of earlystage follicular lymphoma: is it time to change the standard strategy?
JF - Leukemia & Lymphoma
VL - 56
IS - 8
SP - 2350-2356
EP - 2350-2356
PB - Informa Healthcare
SN - 10428194
KW - Follicular lymphoma
KW - rituximab
KW - radiotherapy
N2 - Early-stage follicular lymphoma (FL) has traditionally been treated with involved-fi eld radiotherapy (RT). Rituximab (R) is a low-toxic, effi cient systemic therapy for FL, but there are no data about its clinical impact in early FL. We retrospectively analyzed 93 patients with stage I – II indolent FL treated with RT (n=65) or RT + R (n=14) or R alone (n=14). Median follow-up was 5.0 years for patients with RT, 2.8 years for the RT + R subgroup and 2.5 years for patients treated with R. The complete response rate was 92%, 100% and 86% (not signifi cant) and the median PFS was 3.3 years, not reached and 4.9 years (p=0.035) for the RT, RT + R and R arms, with no impact on overall survival. R combined with RT seems to give better results in terms of global FL control, but longer follow-up and prospective comparison are needed to verify these results.
ER -
JANÍKOVÁ, Andrea, Zbyněk BORTLÍČEK, Vit CAMPR, Natasa KOPALOVA, Katerina BENESOVA, David BELADA, Vit PROCHAZKA, Robert PYTLIK, Samuel VOKURKA, Jan PIRNOS, Juraj DURAS, Heidi MOCIKOVA, Jiří MAYER a Marek TRNENY. Radiotherapy with rituximab may be better than radiotherapy alone in first-line treatment of earlystage follicular lymphoma: is it time to change the standard strategy? \textit{Leukemia \&{} Lymphoma}. London: Informa Healthcare, 2015, roč.~56, č.~8, s.~2350-2356. ISSN~1042-8194. Dostupné z: https://dx.doi.org/10.3109/10428194.2014.990010.
|
